Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]CETO PET for Adrenal Diagnostics
NCT05361083Phase 1Completed
- Sponsor
- Uppsala University
- Start
- Sep 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]CETO in primary aldosteronism (PA), Cushing syndrome, adrenocortical carcinoma (ACC) and 1 more, sponsored by Uppsala University. Primary endpoint: Safety of [18F]CETO administration at 1 day. Started Sep 2019; status: completed.
02
Drugs
[18F]CETO
03
Conditions
primary aldosteronism (PA)Cushing syndromeadrenocortical carcinoma (ACC)Adrenal adenoma
Beyond the preview
Go deeper on NCT05361083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361083.